Coronavirus Vaccine Stocks: How Long Will COVID-19 Immunity Last?

Fool.com's Healthcare and Cannabis Bureau Chief Corinne Cardina interviewed Richard Horton on Motley Fool Live on Oct. 9. Horton runs the British medical journal The Lancet and has been at the forefront of publishing data about the coronavirus pandemic this year. He also recently published a book called The COVID-19 Catastrophe.

Here, Horton explains what investors should know about the length of COVID-19 immunity and how that scientific question impacts the coronavirus candidates in late-stage trials including those being developed by Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX), as well as by Moderna (NASDAQ: MRNA.

 

Continue reading

Source Fool.com